These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774 [TBL] [Abstract][Full Text] [Related]
9. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. McLaughlin VV; Jansa P; Nielsen-Kudsk JE; Halank M; Simonneau G; Grünig E; Ulrich S; Rosenkranz S; Gómez Sánchez MA; Pulido T; Pepke-Zaba J; Barberá JA; Hoeper MM; Vachiéry JL; Lang I; Carvalho F; Meier C; Mueller K; Nikkho S; D'Armini AM BMC Pulm Med; 2017 Dec; 17(1):216. PubMed ID: 29282032 [TBL] [Abstract][Full Text] [Related]
10. Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. Galiè N; Grimminger F; Grünig E; Hoeper MM; Humbert M; Jing ZC; Keogh AM; Langleben D; Rubin LJ; Fritsch A; Davie N; Ghofrani HA J Heart Lung Transplant; 2017 May; 36(5):509-519. PubMed ID: 28190787 [TBL] [Abstract][Full Text] [Related]
15. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262 [TBL] [Abstract][Full Text] [Related]
16. Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. D'Armini AM; Ghofrani HA; Kim NH; Mayer E; Morsolini M; Pulido-Zamudio T; Simonneau G; Wilkins MR; Curram J; Davie N; Hoeper MM J Heart Lung Transplant; 2015 Mar; 34(3):348-55. PubMed ID: 25813765 [TBL] [Abstract][Full Text] [Related]
17. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study. Langleben D; Galiè N; He J; Huang Y; Humbert M; Keogh A; Rubin LJ; Zhou D; Curram J; Davie N; Ghofrani HA J Heart Lung Transplant; 2015 Mar; 34(3):338-47. PubMed ID: 25703961 [TBL] [Abstract][Full Text] [Related]
18. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. Ghofrani HA; D'Armini AM; Grimminger F; Hoeper MM; Jansa P; Kim NH; Mayer E; Simonneau G; Wilkins MR; Fritsch A; Neuser D; Weimann G; Wang C; N Engl J Med; 2013 Jul; 369(4):319-29. PubMed ID: 23883377 [TBL] [Abstract][Full Text] [Related]
19. Rationale and study design of MOTION: A phase 4, prospective, single-arm, open-label study to measure outcomes in patients with pulmonary arterial hypertension not on active treatment. Mathai SC; Minai O; Sullivan SD; Lerner D; Levine D Respir Med; 2017 Jan; 122 Suppl 1():S23-S27. PubMed ID: 27890471 [TBL] [Abstract][Full Text] [Related]
20. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Galiè N; Müller K; Scalise AV; Grünig E Eur Respir J; 2015 May; 45(5):1314-22. PubMed ID: 25657022 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]